Home

 

1055 Westlakes Drive

Suite 200

Berwyn, PA 19312

© 2018 Complexa. All rights reserved.

  • LinkedIn - Grey Circle

Our Research Focus

OVERVIEW    |     PIPELINE  

Complexa is focused on the development of medicines to treat severe and life-threatening diseases involving fibrosis and inflammation.

 

Our lead compound, CXA-10, is an oral nitrated fatty acid compound being advanced for the treatment of focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Both of these diseases are considered life-threatening as they can compromise the function of the kidney and the heart. Current treatment options are limited as they do not address the underlying metabolic, inflammatory and fibrotic drivers of these diseases.

 

The company is currently recruiting patients in two Phase 2 trials, one trial in FSGS and one trial in PAH.

 

Focal Segmental Glomerulosclerosis

 

Focal segmental glomerulosclerosis (FSGS) is a disease that attacks the kidney’s filtering units (glomeruli) causing serious ‘protein spilling’ and tissue scarring which leads to permanent kidney damage and even failure requiring dialysis. An estimated 40,000 individuals are living with FSGS with approximately 7,000 new cases diagnosed yearly in the U.S. FSGS occurs across all age groups. In some cases, there are no symptoms of the disease, however, the most common are protein in the urine (proteinuria) and swelling (edema). FSGS is classified primary or secondary based on the origin of the disease. Primary FSGS is when the disease occurs for unknown reasons and is commonly associated with a serious condition called nephrotic syndrome, whereas secondary FSGS results from other medical conditions. FSGS is progressive, causing scarring (fibrosis) in the kidney that leads to kidney failure, so the goal of treatment is to lessen the amount of protein in the urine. Currently, there are no FDA-approved treatments for FSGS.

 

For more information about FSGS, visit NephCure Kidney International at www.nephcure.org.

Pulmonary Arterial Hypertension

 

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by high pressure (hypertension) in the arteries of the lungs (pulmonary artery) for unknown reason. The pulmonary arteries are the blood vessels that carry blood from the right side of the heart through the lungs. Approximately 30,000 individuals are living with PAH with nearly 1,000 new cases diagnosed yearly. PAH occurs in females more than males with onset between the ages of 30 and 60. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pressure and fatigue. The disease is often misdiagnosed because the symptoms are too mild. Although the origin of PAH is unknown, 15 to 20 percent of patients have heritable PAH. As PAH is progressive, it is important to treat the disease so that the high pressure in the arteries of the lungs does not cause further narrowing of the vessels, resulting in the heart muscle to work harder against higher pressure and weaken. Currently approved treatment options primarily target symptoms without appreciable impact on modifying the underlying disease.